natgillin/translations-raw huggingface dataset:
If you have the impression that the effect of Aripiprazole Mylan Pharma is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Aripiprazol Mylan Pharma premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis. 
Aripiprazol ni indiciran za zdravljenje bolnikov s psihozo, povezano z demenco.
• onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma, 
• pojav sladkorne bolezni (diabetes) ali njeno poslabšanje, ketoacidoza (ketone v krvi ali v urinu) ali koma,
The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population. 
Izračunana točka razmerja tveganja (HR) v celotni populaciji je bila 0,461 (95 % interval zaupanja, 0,242 - 0,879).
Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. 
Stabilizirane bolnike so nato randomizirali tako, da so nadaljevali zdravljenje z istim stabilizatorjem razpoloženja in dvojno slepo uporabo aripiprazola ali placeba.
Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). 
V vseh preizkušanjih z vsemi odmerki aripiprazola so ocenili ravni prolaktina (n = 28.242).
Manic episodes in Bipolar I Disorder 
Manične epizode pri bipolarni motnji I
At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin. 
V terapevtskih koncentracijah je več kot 99 % aripiprazola in dehidroaripiprazola vezanega na beljakovine v serumu, predvsem na albumin.
Maternal toxicity occurred at doses similar to those eliciting developmental toxicity. 
Učinki, toksični za mater, so se pojavili pri odmerkih, podobnih tistim, ki so izzvali razvojne toksične učinke.
However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2). 
Največji dnevni odmerek 30 mg je treba pri bolnikih s hudo okvaro jeter uporabljati previdno (glejte poglavje 5.2).
In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years). 
V istih preskušanjih so poročali o cerebrovaskularnih neželenih učinkih (npr. možganski kapi, prehodnem ishemičnem napadu), vključno s smrtnimi primeri (povprečna starost bolnikov: 84 let, razpon: 78-88 let).
Potential for aripiprazole to affect other medicinal products 
Možnost vpliva aripiprazola na druga zdravila
• difficulty in passing urine, 
• težave pri odvajanju urina,
Each tablet of 5, 10, 15, 30 mg containing 5, 10, 15, 30 mg of aripiprazole respectively. 
Ena 5, 10, 15, 30 mg tableta vsebuje 5, 10, 15, 30 mg aripiprazola.
Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. 
Ukrepanje v primeru prevelikega odmerjanja mora biti osredotočeno na podporno zdravljenje, vzdrževanje ustreznega stanja dihal, oksigenacijo in ventilacijo ter obvladovanje simptomov.
In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. 
V kliničnih preskušanjih in izkušenj v obdobju trženja zdravila so ugotovili naključno ali namerno preveliko odmerjanje aripiprazola samega pri odraslih bolnikih z ocenjenimi odmerki do 1.260 mg brez smrtnih primerov.
In adults it also prevents this condition from returning in patients who have responded to the treatment with Aripiprazole Mylan Pharma. 
Zdravilo tudi preprečuje ponovitve bolezni pri odraslih bolnikih, ki so se odzvali na zdravljenje z zdravilom Aripiprazol Mylan Pharma.
• feeling restless and unable to keep still, difficulty sitting still, 
• občutek nemira in nezmožnost sedenja ali stanja pri miru,
If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued. 
Če se pri bolniku pojavijo znaki in simptomi MNS-a ali ima nepojasnjeno zvišanje telesne temperature brez drugih kliničnih znakov MNS-a, je treba ukiniti vse antipsihotike, vključno z aripiprazolom.
In both of these short term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. 
Klinična pomembnost rezultatov za učinkovitost v obeh kratkih preskušanjih ni bila ugotovljena, zaradi magnitude učinka zdravila v primerjavi z velikim učinkom placeba in nejasnega vpliva na psihosocialno delovanje.
Other medicines and Aripiprazole Mylan Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Druga zdravila in zdravilo Aripiprazol Mylan Pharma Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zdravili, ki ste jih dobili brez recepta.
A gastric acid blocker, the H2 antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. 
Zaviralec izločanja želodčne kisline, antagonist H2 famotidin, zmanjša hitrost absorpcije aripiprazola, vendar ta učinek ne velja za klinično pomembnega.
• feeling tired. 
• utrujenost.
The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). 
Celotni delež dokončanja je bil pri bolnikih, ki so dobivali aripiprazol, značilno večji (43 %) kot pri tistih, ki so dobivali haloperidol (30 %).
Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. 
Drugi impulzi, o katerih poročajo, so: povečan spolni nagon, kompulzivno nakupovanje, kompulzivno prenajedanje in drugo impulzivno in kompulzivno vedenje.
Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes. 
Zato ni verjetno, da bi aripiprazol povzročil klinično pomembno medsebojno delovanje prek teh encimov.
Valproate and lithium 
Valproat in litij
It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. 
Uporablja se pri odraslih in mladostnikih, starih 15 let in več, za zdravljenje bolezni s simptomi, kakršni so slišanje, videnje ali občutenje stvari, ki jih v resnici ni, sumničavost, zmotna prepričanja, nepovezano govorjenje in vedenje ter čustvena praznost.
Aripiprazole Mylan Pharma with food, drink and alcohol This medicine can be taken regardless of meals. 
Zdravilo Aripiprazol Mylan Pharma skupaj s hrano, pijačo in alkoholomTo zdravilo lahko jemljete ne glede na obroke.
In these patients dosing should be managed cautiously. 
Pri teh bolnikih mora biti odmerjanje previdno.
Aripiprazole may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls. 
Aripiprazol lahko povzroči somnolenco, posturalno hipotenzijo, motorično in senzorično nestabilnost, ki lahko privedejo do padcev.
In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). 
V preskušanju, nadzorovanem s haloperidolom, je bil delež odzivnih bolnikov, pri katerih se je odziv na zdravilo ohranil po 52 tednih, v obeh skupinah podoben (aripiprazol 77 % in haloperidol 73 %).
The safety profile included weight gain and changes in prolactin levels. 
Profil varnosti je vključeval podatke o povečanju telesne mase in spremembah vrednosti prolaktina.
The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms. 
Med možnimi medicinsko resnimi znaki in simptomi so bili somnolenca, prehodna izguba zavesti in ekstrapiramidni simptomi.
All ADRs are listed by system organ class and frequency; very common (≥ 1 /10), common (≥ 1/100 to< 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Vsi neželeni učinki zdravila so našteti po organskih sistemih in pogostnosti: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
It does not matter whether you take it with or without food. 
Ni pomembno, ali jo vzamete s hrano ali brez nje, vedno pa jo vzemite z vodo in jo pogoltnite celo.
Sudden unexplained death Torsades de pointes QT prolongation Ventricular arrhythmias Cardiac arrest Bradycardia 
Srčne bolezni tahikardija nenadna nepojasnjena smrt torsades de pointes podaljšanje intervala QT ventrikularna aritmija zastoj srca bradikardija
Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. 
Aripiprazol učinkovito vzdržuje klinično izboljšanje med nadaljevalnim zdravljenjem pri odraslih bolnikih, ki se uvodoma odzovejo na terapijo.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered nongenotoxic. 
Na podlagi celotnega spektra standardnih preskusov genotoksičnosti je bilo ocenjeno, da aripiprazol ni genotoksičen.
Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8). 
Čeprav so se vzroki smrti razlikovali, je bila večina vzrokov kardiovaskularnih (npr. srčno popuščanje, nenadna smrt) ali infekcijskih (npr. pljučnica) (glejte poglavje 4.8).
If you take more Aripiprazole Mylan Pharma than you should If you realise you have taken more Aripiprazole Mylan Pharma than your doctor has recommended (or if someone else has taken some of your Aripiprazole Mylan Pharma), contact your doctor right away. 
Če ste vzeli večji odmerek zdravila Aripiprazol Mylan Pharma, kot bi smeli Če ugotovite, da ste vzeli več zdravila Aripiprazol Mylan Pharma, kot vam je priporočil zdravnik (ali če je vaše zdravilo Aripiprazol Mylan Pharma vzel kdo drug), se takoj posvetujte s svojim zdravnikom.
In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. 
V tem preskušanju so raziskovalci bolnike najprej razporedili na odprto zdravljenje samo z litijem ali valproatom, da bi ugotovili delni neodziv.
Orodispersible tablets or oral solution may be used as an alternative to Aripiprazole Mylan Pharma tablets for patients who have difficulty swallowing Aripiprazole Mylan Pharma tablets (see section 5.2). 
Orodisperzibilne tablete ali peroralna raztopina se lahko uporabijo kot alternativa tabletam Aripiprazol Mylan Pharma pri bolnikih, ki tablete Aripiprazol Mylan Pharma težko pogoltnejo (glejte poglavje 5.2).
Therefore, aripiprazole is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1). 
Uporabe aripiprazola se zato pri bolnikih, mlajših od 13 let, ne priporoča (glejte poglavji 4.8 in 5.1).
Aripiprazole Mylan Pharma contains the active substance aripiprazole and belong to a group of medicines called antipsychotics. 
Zdravilo Aripiprazol Mylan Pharma vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
Irritability associated with autistic disorder: the safety and efficacy of aripiprazole in children and adolescents aged below 18 years have not yet been established. 
Razdražljivost, povezana z avtistično motnjo: varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
• high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite and feeling weak) or family history of diabetes 
• imate visok krvni sladkor (značilni simptomi so prekomerna žeja, izločanje velikih količin urina, povečanje apetita in šibkost) ali sladkorno bolezen v družini,
Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing. 
Aripiprazol se dobro absorbira in doseže največjo koncentracijo v plazmi v 3 do 5 urah po uporabi.
• SSRI s (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety 
• SSRI (kot sta paroksetin in fluoksetin) uporabljamo za depresijo, OCD, paniko in anksioznost,
The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights. 
Farmakokinetika aripiprazola in dehidroaripiprazola pri pediatričnih bolnikih, starih od 10 do 17 let, je po korekciji glede na razliko v telesni masi podobna farmakokinetiki pri odraslih.
After a 13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. 
Po 13-26 tednih stabilizacije na aripiprazolu (2-15 mg/dan) so bolniki s stabilnim odzivom nadaljnjih 16 tednov bodisi ostali na aripiprazolu ali pa so prešli na placebo.
Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17% of patients, with tremor accounting for 6.5%. 
O ekstrapiramidnih simptomih so poročali predvsem med stabilizacijsko fazo, in sicer pri 17 % bolnikov, od tega je 6,5 % predstavljal tremor.
When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. 
Če se pojavi, se ponavadi pojavi pri bolnikih s pomembnimi dejavniki tveganja, npr. anamnezo diabetesa, motnjami ščitnice ali adenomom hipofize.
Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. 
Razvojne toksične učinke, vključno z od odmerka odvisno zapoznelo fetalno osifikacijo in možnimi teratogenimi učinki, so pri podganah opažali v odmerkih, ki so povzročili subterapevtsko izpostavljenost (na podlagi AUC), in pri kuncih v odmerkih, ki so povzročili izpostavljenost 3- in 11kratne srednje AUC v stanju dinamičnega ravnovesja ob največjem priporočenem kliničnem odmerku.
Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in na škatli za oznako ‘'Uporabno do:''/EXP:''.
Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers. 
Po vsakem potrjenem prevelikem odmerjanju ali sumu na preveliko odmerjanje aripiprazola je potreben skrben zdravstveni nadzor in spremljanje, dokler si bolnik ne opomore.
It is important that you carry on taking Aripiprazole Mylan Pharma for as long as your doctor has told you to. 
Pomembno je, da zdravljenje z zdravilom Aripiprazol Mylan Pharma nadaljujete tako dolgo, kot vam je svetoval zdravnik.
Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. 
V randomizirani fazi so tako ovrednotili štiri podskupine stabilizatorjev razpoloženja: aripiprazol + litij, aripiprazol + valproat, placebo + litij in placebo + valproat.
Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. 
Aripiprazol je imel tudi zmerno vezavno afiniteto za mesta ponovnega privzema serotonina in nobene opazne afinitete za muskarinske receptorje.
In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia. 
Pri pediatrični populaciji so o somnolenci in utrujenosti poročali pogosteje pri bolnikih z bipolarno motnjo, kot pri bolnikih s shizofrenijo.
• loss of appetite (anorexia), 
• izguba apetita (neješčnost),
Urinary incontinence Urinary retention 
Bolezni sečil urinska inkontinanca retencija urina
However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. 
Opisana sta tudi zvišanje kreatin-fosfokinaze in rabdomioliza, ne nujno v povezavi z MNS.
Treatment should be initiated at 2 mg (using an appropriate aripiprazole containing medicinal product) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. 
Zdravljenje je treba uvesti v odmerku 2 mg (uporaba primernega zdravila, ki vsebuje aripiprazol), ki ga bolnik jemlje 2 dni, nato pa se odmerek poveča do odmerka 5 mg, ki ga bolnik jemlje še dodatna 2 dni.
These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings. 
To so imenuje motnja nadzora impulzov, kamor štejemo vedenja, kot so odvisnost od hazardiranja, čezmerno uživanje hrane ali trošenje denarja, nenormalno povečan libido ali preokupacija z mislimi na spolnost ali spolnimi občutki.
In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). 
V kliničnih študijah odmerki od 10 do 30 mg aripiprazola na dan niso pomembno vplivali na presnovo substratov CYP2D6 (razmerje dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ali CYP3A4 (dekstrometorfan).
Gender No dosage adjustment is required for female patients as compared to male patients (see section 5.2). 
Spol Pri bolnicah v primerjavi z bolniki odmerka ni treba prilagajati (glejte poglavje 5.2).
Patients treated with any antipsychotic, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8). 
Bolnike, ki dobivajo katerikoli antipsihotik, vključno z aripiprazolom, je treba opazovati glede znakov in simptomov hiperglikemije (npr. polidipsije, poliurije, polifagije in šibkosti); bolnike z diabetesom mellitusom ali dejavniki tveganja zanj pa je treba redno nadzirati, da bi odkrili poslabšanje urejenosti glukoze (glejte poglavje 4.8).
However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of in vitro solubility. 
Vendar je bila koncentracija sulfatnih konjugatov hidroksiaripiprazola v človeškem žolču v 39-tedenski raziskavi ob največjem priporočenem odmerku 30 mg na dan le 6 % koncentracije v žolču pri opicah ter je bila bistveno pod mejo (6 %) njihove topnosti in vitro.
• abnormal muscle breakdown which can lead to kidney problems, 
• nenormalna razgradnja mišic, ki lahko povzroči težave z ledvicami,
Aripiprazole may cause sleepiness, fall in blood pressure when standing up, dizziness and changes in your ability to move and balance, which may lead to falls. 
Aripiprazol lahko povzroči zaspanost, padec krvnega tlaka v stoječem položaju, omotico in spremembe v sposobnosti gibanja in ravnotežja, kar lahko privede do padcev.
Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain: 
Zdravila, ki povečajo raven serotonina, navadno uporabljamo za bolezni, vključno z depresijo, generalizirano anksiozno motnjo, obsesivno-kompulzivno motnjo (OCD- obsessive compulsive disorder) in socialno fobijo, kot tudi migrene in bolečine:
Pharmathen International S.A Industrial Park Sapes, Rodopi Prefecture, Block No 5, Rodopi 69300, 
Pharmathen International S.A Industrial Park Sapes, Rodopi Prefecture, Block No 5,
The safety profile in a 26-week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial. 
V 26-tedenskem, odprtem, podaljšanem preskušanju je bil profil varnosti podoben profilu varnosti v kratkotrajnem, s placebo nadzorovanem preskušanju.
Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. 
Aripiprazol se presnavlja po več poteh, ki vključujejo encime CYP2D6 in CYP3A4, ne pa encimov CYP1A.
If you notice you are gaining weight, develop unusual movements, experience somnolence that interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell your doctor. 
Če opazite povečevanje telesne mase, pojav neobičajnih gibov, pretirano zaspanost, ki vpliva na običajne dnevne aktivnosti, težave s požiranjem ali znake alergije, o tem obvestite svojega zdravnika.
• triptans (such as sumatriptan and zolmitripitan) used for treating migraine 
• triptane (kot sta sumatriptan in zolmitriptan) uporabljamo za zdravljenje migrene.
• reports of abnormal liver test values, 
• primeri nenormalnih izvidov laboratorijskih jetrnih preiskav,
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo. 
V treh s placebom nadzorovanih preskušanjih (n = 938, povprečna starost: 82,4 leta, razpon: 5699 let) aripiprazola pri starejših bolnikih s psihozo, povezano z Alzheimerjevo boleznijo, je bilo tveganje smrti večje pri bolnikih, ki so dobivali aripiprazol, kot pri tistih, ki so dobivali placebo.
Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8). 
Aripiprazol je treba uporabljati previdno pri bolnikih z družinsko anamnezo podaljšanja intervala QT (glejte poglavje 4.8).
Tics associated with Tourette's disorder: the safety and efficacy of aripiprazole in children and adolescents 6 to 18 years of age have not yet been established. 
Trzaji, povezani s Tourettovim sindromom: varnost in učinkovitost aripiprazola pri otrocih in mladostnikih, starih od 6 do 18 let, še ni bila dokazana.
In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients. 
Nasprotno pa je bil 95 % interval zaupanja za razmerje tveganja pri starejši skupini (aripiprazol, n = 69; placebo, n = 36) 0,242 do 0,879, torej se pri starejših bolnikih lahko naredi sklepe o učinku zdravljenja.
The safety and efficacy of aripiprazole in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. 
Varnost in učinkovitost aripiprazola nista ugotovljeni pri zdravljenju shizofrenije ali maničnih epizod pri bipolarni motnji I pri bolnikih, starih 65 let in starejših.
Additionally, aripiprazole and dehydroaripiprazole did not show potential for altering CYP1A2-mediated metabolism in vitro. 
Poleg tega aripiprazol in dehidroaripiprazol in vitro nista pokazala potenciala za spreminjanje presnove s CYP1A2.